Bio-Rad Introduces S3e™ Cell Sorter (488/640 nm)


The New Model Offers Lasers Configured Specifically for Immunologists

Hercules, CA — April 27, 2015 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of the easy-to-use S3e Cell Sorter (488/640 nm). This latest addition to the company’s series of S3e Cell Sorters incorporates the fluorescence wavelengths commonly used by immunologists.

Traditionally, cell sorters have primarily been available in core labs due to the high cost, size, and complexity of these instruments. With the introduction of Bio-Rad’s easy-to-use benchtop S3 Cell Sorter in 2013, many more scientists were able to sort cells in their own labs.

Immunologists customarily use the 640 nm wavelength to excite and detect red fluorophores, such as allophycocyanin (APC) and APC-Cy7. The new S3e Cell Sorter possesses the 488/640 nm laser combination, thus extending the convenience of benchtop cell sorting to immunologists.

The S3e Cell Sorter allows immunologists at SUNY Downstate to sort cells in their own laboratory.

Like all instruments in the S3e series, the S3e Cell Sorter (488/640 nm) offers a hands-free startup sequence that automatically aligns the stream to optics and optimizes the droplet/side stream. This capability along with other features of the instrument allows scientists to begin sorting more quickly than they could with other, more complex systems. In addition, the S3e Cell Sorter’s ability to prevent tubes from running dry or overfilling ensures that precious sample is never lost. All these features are available without the prohibitive size and cost of more complex cell sorters.

Key benefits of all S3e Cell Sorters include:

  1. Simplified setup — a hands-free startup sequence automatically aligns lasers and calculates tedious drop delay measurements
  2. Two-way cell sorting — use one or two lasers and up to four detectors to sort two defined populations simultaneously
  3. High speed and high purity — sort cells quickly and accurately

For more information about the S3e Cell Sorter (488/640 nm), please visit

About the Cell Biology Portfolio
The cell biology product portfolio from Bio-Rad Laboratories comprises solutions for researchers conducting experiments that involve cell culture, cellular imaging, and cell analysis. Bio-Rad is a well-established provider of transfection tools, particularly through its line of Gene Pulser® Electroporation Systems. The company has expanded its cell biology offerings to include the S3eCell Sorter, the ZOE™ Fluorescent Cell Imager, and the TC20™ Automated Cell Counter. These instruments are supported by a suite of flow cytometry and fluorescent cell imaging reagents, including ReadiLink Antibody Labeling Kits. In addition, more than 10,500 antibodies and associated kits and accessories are available for various cell biology applications from AbD Serotec®, a Bio-Rad company. Visit for more information.

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 7,600 people worldwide and had revenues exceeding $2.1 billion in 2014. For more information, please visit

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

For more information contact:
Steve Kulisch

Ken Li
Chempetitive Group
312-997-2436 x 112